In a virtual panel discussion about public and population health at J.P. Morgan's annual conference, the CEO of Aledade shared how the quest for efficiency in a world of harried physicians' practices almost led Aledade to use a flawed ML algorithm to engage at-risk patients of those practices.
The company started with genetic testing, but expanded to Covid-19 tests and vaccines during the pandemic. It's valuation has tripled since it last raised a funding round valuing it at $1.5 billion in January.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The company, which got started in genomic testing, has quickly expanded its services to include providing Covid-19 testing at businesses and universities. With the new funding, it plans to build infrastructure for more preventive health services.
The future of precision medicine will come only as quickly as doctors can pick out clinically useful information from the genetic data being gathered on their patients.
The Rochester, Minnesota-based healthcare system and San Mateo, California-based population genomics company plan to launch the study in the next few weeks.
Color vice president for research and scientific affairs Alicia Zhou explained that there is an ethical obligation to provide information on actionable genes, but costs and logistics have previously made doing so prohibitive.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
In addition to its expansion into bioengineering, the early stage venture capital firm has also shifted its investment strategy to include strategic growth investments.
Is hereditary cancer screening really worth it for the general population? Increasingly, the answer is 'yes.'